Candel Therapeutics Highlights CAN-2409 Breakthrough Results
Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a leading clinical-stage biopharmaceutical company dedicated to cancer treatment innovation, is gearing up to host a pivotal conference call. Scheduled for June 3, 2025, at 1:00 PM ET, this call will delve into the promising phase 3 clinical trial results for CAN-2409 in the treatment of localized, intermediate-to-high-risk prostate cancer.
Details of the Conference Call
The much-anticipated conference call will discuss CAN-2409's groundbreaking results, highlighting a substantial 30% reduction in disease recurrence when combined with standard radiation therapy compared to a placebo. This presentation will stem from the insightful discourse delivered by Dr. Theodore DeWeese at the recent American Society of Clinical Oncology (ASCO) Annual Meeting.
Expert Insights on CAN-2409
Joining the discussion are two eminent prostate cancer specialists, Dr. John E. Sylvester and Dr. Ronald F. Tutrone, Jr. Both physicians served as principal investigators in the phase 3 clinical trial, bringing their extensive knowledge and experience to the forefront of this important conversation.
Dr. Sylvester, with over two decades of expertise in radiation oncology, is known for his innovative techniques in prostate brachytherapy. His contributions to the field have significantly shaped clinical practices, not only in the U.S. but also globally. He has a healthy portfolio of peer-reviewed publications and is deeply committed to improving patient outcomes.
On the other hand, Dr. Tutrone is a highly respected urologist, specializing in prostate cancer management. His leadership at Chesapeake Urology Research Associates is complemented by a history of active involvement in clinical trials focused on urologic oncology. His work continues to impact the landscape of prostate cancer treatment positively, as he persistently advocates for patient-centered approaches and groundbreaking research.
Webcast and Registration Information
Investors and stakeholders are encouraged to participate in this important discussion by registering for the webcast and conference call. The event will be accessible through Candel's official website. Attendees are advised to join 10 minutes early, ensuring they receive comprehensive insights on CAN-2409's potential impact on prostate cancer treatment.
About CAN-2409
CAN-2409, also known as aglatimagene besadenovec, represents Candel's most advanced therapeutic candidate designed as a replication-defective adenovirus. It is engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene, activating the immune response against tumors. This innovative approach capitalizes on the local administration of valacyclovir to generate a cytotoxic effect against cancer cells, forming a targeted immune response that is particularly effective for various solid tumors.
Currently, CAN-2409 is under further evaluation across multiple oncology fronts, including non-small cell lung cancer and borderline resectable pancreatic adenocarcinoma. Its recent success in prostate cancer has led to Fast Track Designation by the U.S. Food and Drug Administration (FDA), emphasizing its potential to shift treatment paradigms within oncology.
Candel Therapeutics: Innovating Cancer Treatment
Candel Therapeutics is committed to developing cutting-edge biological immunotherapies that tailor treatment to individual patient needs. Their two platforms revolve around genetically modified adenoviruses and HSV gene constructs, enabling diverse therapeutic options for cancer patients. The success of CAN-2409 underscores the Company’s mission to provide hope through innovative cancer therapies.
Engaging with Candel
To discover more about Candel's pioneering work and the advancements in cancer treatment, stakeholders can visit their official site. The upcoming conference call will further illuminate the clinical advancements that can potentially transform the landscape of prostate cancer treatment.
Frequently Asked Questions
What is CAN-2409?
CAN-2409 is an investigational biological immunotherapy designed to elicit a targeted immune response against tumors, particularly in prostate cancer.
Who are the key experts speaking on the conference call?
Dr. John E. Sylvester and Dr. Ronald F. Tutrone, Jr., both experienced urologists and principal investigators in the CAN-2409 clinical trial, will provide insights during the call.
How does CAN-2409 work?
CAN-2409 utilizes a replication-defective adenovirus to deliver the HSV-tk gene to cancer cells, promoting an immune response that helps reduce tumor recurrence.
What were the trial results for CAN-2409?
The phase 3 clinical trial revealed a notable 30% reduction in disease recurrence when CAN-2409 was combined with standard radiation therapy versus a placebo.
How can I participate in the conference call?
Interested participants can register for the call through Candel Therapeutics' official website to receive dial-in information.
